Table 1. Baseline characteristics of the subset of subjects with CKD-MBD measurements according to study group.
| Placebo (n = 34) |
Allopurinol (n = 29) |
|
|---|---|---|
| Age (years) | 58.0 ± 9.6 | 59.2 ± 12.9 |
| Gender (Male) | 27 (79%) | 24 (83%) |
| Race | ||
| Caucasian | 29 (85%) | 18 (62%) |
| African American | 3 (9%) | 7 (24%) |
| Other | 2 (6%) | 4 (14%) |
| Hispanic ethnicity | 9 (27%) | 5 (17%) |
| History of DM | 21 (62%) | 19 (66%) |
| CKD-EPI eGFR (mL/min/1.73m2) | 40.8 ± 8.4 | 40.3 ± 9.3 |
| Serum urate (mg/dL) | 8.81 ± 1.4 | 8.39 ± 1.4 |
| CIMT (mm) | 0.77 ± 0.17 | 0.73 ± 0.14 |
| Serum T50 (min) | 274 ± 56 | 244 ± 53 |
| Calcium (mg/dL) | 9.4 ± 0.4 | 9.1 ± 0.4 |
| Phosphorus (mg/dL) | 3.6 ± 0.6 | 3.6 ± 0.5 |
| 25 vitamin D (ng/mL) | 29.4 ± 10.1 | 26.8 ± 8.1 |
| Total 1,25 vitamin D (pg/mL) | 28.0 ± 12.0 | 27.2 ± 11.0 |
| 24,25 vitamin D (pg/mL) | 3.4 ± 1.9 | 3.2 ± 1.8 |
| iPTH (pg/mL) | 73.8 ± 40.8 | 68.4 ± 32.4 |
| FGF-23 (pg/mL)-Median (IQR) | 110.4(92.7,150.4) | 74.1(57.3,104.9)* |
Values are expressed as means ± standard deviation or % = percent of patients unless otherwise noted iPTH = intact parathyroid hormone; FGF-23 = fibroblast growth factor-23
*: p value <0.05